These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 20532015)
1. Regulation of glucose control in people with type 2 diabetes: a review and consensus. Woo JT; Park KS; Byun DW; Ko KS; Chung YS; Kim DM; Park TS; Cha BS; Lee IK; Park JY; Son HS; Lee MK; Kim KW; Son HY Korean Diabetes J; 2010 Feb; 34(1):16-20. PubMed ID: 20532015 [TBL] [Abstract][Full Text] [Related]
2. Erratum: "Does COVID-19 vaccination increase the risk of interstitial lung disease at a population level?" Taehee Kim, Hyun Lee, Cho Yun Jeong, Sang Woo Yeom, Bo-Guen Kim, Tai Sun Park, Dong Won Park, Ji-Yong Moon, Tae-Hyung Kim, Jang Won Sohn, Ho Joo Yoon, Sang-Heon Kim and Jong Seung Kim. ERJ Open Res; 2024 Jul; 10(4):. PubMed ID: 39193380 [TBL] [Abstract][Full Text] [Related]
3. Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. van Steen SC; Woodward M; Chalmers J; Li Q; Marre M; Cooper ME; Hamet P; Mancia G; Colagiuri S; Williams B; Grobbee DE; DeVries JH; Diabetologia; 2018 Apr; 61(4):780-789. PubMed ID: 29308539 [TBL] [Abstract][Full Text] [Related]
4. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Akalin S; Berntorp K; Ceriello A; Das AK; Kilpatrick ES; Koblik T; Munichoodappa CS; Pan CY; Rosenthall W; Shestakova M; Wolnik B; Woo V; Yang WY; Yilmaz MT; Int J Clin Pract; 2009 Oct; 63(10):1421-5. PubMed ID: 19769698 [TBL] [Abstract][Full Text] [Related]
5. Glycaemic control and cardiovascular morbi-mortality: the contribution of the 2008 studies. Cugnet-Anceau C; Bauduceau B Ann Endocrinol (Paris); 2009 Mar; 70(1):48-54. PubMed ID: 19193363 [TBL] [Abstract][Full Text] [Related]
6. [Current controversies in glycemic control targets. What do the results of the latest clinical trials tell us about the approach to type 2 diabetes mellitus?]. Mauricio D; Rius F Med Clin (Barc); 2010 Sep; 135 Suppl 2():2-5. PubMed ID: 21420530 [TBL] [Abstract][Full Text] [Related]
8. Implications of new diabetes treatment trials: should current clinical practice be altered? Kravetz JD; Federman DG Postgrad Med; 2009 May; 121(3):67-72. PubMed ID: 19491542 [TBL] [Abstract][Full Text] [Related]
9. Megatrials in type 2 diabetes. From excitement to frustration? Del Prato S Diabetologia; 2009 Jul; 52(7):1219-26. PubMed ID: 19373446 [TBL] [Abstract][Full Text] [Related]
10. The kidney and cardiovascular outcome trials. Bloomgarden Z J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006 [TBL] [Abstract][Full Text] [Related]
11. Glycemic targets for patients with type 2 diabetes mellitus. Hamnvik OP; McMahon GT Mt Sinai J Med; 2009 Jun; 76(3):227-33. PubMed ID: 19421966 [TBL] [Abstract][Full Text] [Related]
12. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Kengne AP; Patel A; Colagiuri S; Heller S; Hamet P; Marre M; Pan CY; Zoungas S; Grobbee DE; Neal B; Chalmers J; Woodward M; Diabetologia; 2010 May; 53(5):821-31. PubMed ID: 20157695 [TBL] [Abstract][Full Text] [Related]
13. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Tandon N; Ali MK; Narayan KM Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193 [TBL] [Abstract][Full Text] [Related]
14. Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial. Joshi R; Galan B; Chalmers J; Perkovic V; Patel A Expert Rev Endocrinol Metab; 2009 Mar; 4(2):111-118. PubMed ID: 30780861 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice? Eckel RH; Farooki A; Henry RR; Koch GG; Leiter LA Clin Diabetes; 2019 Oct; 37(4):316-337. PubMed ID: 31660005 [No Abstract] [Full Text] [Related]
16. [Treatment of diabetes in metabolic syndrome]. Pelikánova T Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868 [TBL] [Abstract][Full Text] [Related]
17. Hypothesis: Intensive insulin therapy-induced mortality is due to excessive serotonin autoinhibition and autonomic dysregulation. Das UN World J Diabetes; 2010 Sep; 1(4):101-8. PubMed ID: 21537434 [TBL] [Abstract][Full Text] [Related]
18. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. Garvey WT; Mechanick JI; Brett EM; Garber AJ; Hurley DL; Jastreboff AM; Nadolsky K; Pessah-Pollack R; Plodkowski R; Endocr Pract; 2016 Jul; 22 Suppl 3():1-203. PubMed ID: 27219496 [TBL] [Abstract][Full Text] [Related]
19. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Zoungas S; Arima H; Gerstein HC; Holman RR; Woodward M; Reaven P; Hayward RA; Craven T; Coleman RL; Chalmers J; Lancet Diabetes Endocrinol; 2017 Jun; 5(6):431-437. PubMed ID: 28365411 [TBL] [Abstract][Full Text] [Related]